Drugs / EBOV GP Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02370589 | Feb 2015 → Apr 2016 | Ebola hemorrhagic fever | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBOV GP Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02370589 ↗ |
| Modality | Vaccine | “Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine” NCT02370589 ↗ |
| Route | Intramuscular | “two IM doses at a 21-day interval” NCT02370589 ↗ |